Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues.
Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma? What can we look forward to through the end of the year and beyond?

Related Content

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

Article

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Woman wearing Enfuse injector | image credit: Enable Injections

Subcutaneous Isatuximab Meets Primary End Points in Phase 3 Study for MM

January 9th 2025

Article

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com

Study Advocates Immunological Value of COVID-19 Vaccination in MM

January 9th 2025

Article

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.

ICYMI: Highlights From ASH 2024

December 29th 2024

Article

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.